CA3039040A1 - Functional rna and small-molecule drug therapeutic complexes and nanoparticle delivery vehicles - Google Patents

Functional rna and small-molecule drug therapeutic complexes and nanoparticle delivery vehicles Download PDF

Info

Publication number
CA3039040A1
CA3039040A1 CA3039040A CA3039040A CA3039040A1 CA 3039040 A1 CA3039040 A1 CA 3039040A1 CA 3039040 A CA3039040 A CA 3039040A CA 3039040 A CA3039040 A CA 3039040A CA 3039040 A1 CA3039040 A1 CA 3039040A1
Authority
CA
Canada
Prior art keywords
molecule
composition
cell
functional rna
small
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3039040A
Other languages
English (en)
French (fr)
Inventor
Omar K. Haffar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eos Biosciences Inc
Original Assignee
Eos Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eos Biosciences Inc filed Critical Eos Biosciences Inc
Publication of CA3039040A1 publication Critical patent/CA3039040A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3039040A 2016-10-03 2017-10-03 Functional rna and small-molecule drug therapeutic complexes and nanoparticle delivery vehicles Abandoned CA3039040A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662403595P 2016-10-03 2016-10-03
US62/403,595 2016-10-03
PCT/US2017/054884 WO2018067526A1 (en) 2016-10-03 2017-10-03 Functional rna and small-molecule drug therapeutic complexes and nanoparticle delivery vehicles

Publications (1)

Publication Number Publication Date
CA3039040A1 true CA3039040A1 (en) 2018-04-12

Family

ID=61831202

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3039040A Abandoned CA3039040A1 (en) 2016-10-03 2017-10-03 Functional rna and small-molecule drug therapeutic complexes and nanoparticle delivery vehicles

Country Status (7)

Country Link
US (1) US20190240344A1 (https=)
EP (1) EP3518939A4 (https=)
JP (1) JP2019529571A (https=)
CN (1) CN109890393A (https=)
AU (1) AU2017339456A1 (https=)
CA (1) CA3039040A1 (https=)
WO (1) WO2018067526A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
JP6608370B2 (ja) 2014-01-17 2019-11-20 シーダーズ―シナイ メディカル センター 受容体標的化構築物およびその使用
CA3087325A1 (en) * 2018-01-02 2019-07-11 Cedars-Sinai Medical Center Nanoparticles for the targeted delivery of therapeutic polypeptides
CN109432430B (zh) * 2018-11-22 2021-12-17 华南理工大学 一种siRNA和抗癌药物疏水性复合物及其制备方法与应用
JP7698252B2 (ja) * 2019-09-06 2025-06-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 治療薬の核酸媒介性送達

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4813712B2 (ja) * 1999-08-09 2011-11-09 ザ ジェネラル ホスピタル コーポレーション 薬物−担体複合体およびその使用方法
CA2881743A1 (en) * 2002-09-25 2004-04-08 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
WO2009009441A2 (en) * 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
JP5252618B2 (ja) * 2007-10-26 2013-07-31 独立行政法人産業技術総合研究所 ＲＮＡ干渉効果が高い芳香環修飾ｓｉＲＮＡ
WO2010085665A2 (en) * 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
JP6608370B2 (ja) * 2014-01-17 2019-11-20 シーダーズ―シナイ メディカル センター 受容体標的化構築物およびその使用
BR112018074304A2 (pt) * 2016-05-27 2019-10-01 Cedars Sinai Medical Center composições de nanopartículas, kit e método para tratar um indivíduo com câncer resistente a fármacos

Also Published As

Publication number Publication date
CN109890393A (zh) 2019-06-14
EP3518939A1 (en) 2019-08-07
JP2019529571A (ja) 2019-10-17
AU2017339456A1 (en) 2019-04-11
EP3518939A4 (en) 2020-06-24
US20190240344A1 (en) 2019-08-08
WO2018067526A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
US20250255978A1 (en) Drug-delivery nanoparticles and treatments for drug-resistant cancer
US20190240344A1 (en) Functional rna and small-molecule drug therapeutic complexes and nanoparticle delivery vehicles
Joshi et al. Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression
JP2024503623A (ja) カプセル化ｒｎａポリヌクレオチド及び使用方法
JP6847852B2 (ja) 癌治療のためのヒト抗原Ｒ発現のｓｉＲＮＡ阻害
JP2024122983A (ja) 組織におけるコード化リボ核酸の標的化送達、発現および調節のための組成物およびプロセス
CN103655475B (zh) 靶向的脂质体
WO2014165296A9 (en) Methods and formulations to achieve tumor targeted double stranded rna mediated cell death
US20240360445A1 (en) CANCER TREATMENT USING siRNA TO MODULATE EXPRESSION OF PRDM2/RIZ PROTEIN
Serpico et al. Lipid nanoparticles-based RNA therapies for breast cancer treatment
CN112236130A (zh) 使用外排体对癌基因的治疗性靶向
Seraj et al. Cytoplasmic expression of EGFR shRNA using a modified T7 autogene-based hybrid mRNA/DNA system induces long-term EGFR silencing and prolongs antitumor effects
Ferreira et al. Smart Targeted-Nanocarriers for Cancer Therapeutics
CN116322782A (zh) 单结构域抗体、皂苷和效应分子的缀合物，包含其的药物组合物，所述药物组合物的治疗用途
US12139713B2 (en) Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell
US20260125688A1 (en) Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target Cell
US20180230466A1 (en) Methods for treating tumors
TW202402305A (zh) 癌症治療之免疫增強
WO2024130257A2 (en) In vivo and ex vivo production of car-neutrophils and use thereof to treat and image cancer
M Knapp Engineering siRNA Lipid Nanoparticles for the Treatment of Mantle Cell Lymphoma
CN118434452A (zh) 用于红细胞介导的递送活性药物成分至靶细胞的治疗化合物
WO2022104006A9 (en) Gpc3 aptamers and variants and use thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20240116